CareDxCDNA
CDNA
About: CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
Employees: 643
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
700% more first-time investments, than exits
New positions opened: 72 | Existing positions closed: 9
204% more call options, than puts
Call options by funds: $4.18M | Put options by funds: $1.38M
92% more capital invested
Capital invested by funds: $841M [Q2] → $1.61B (+$771M) [Q3]
67% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 5 (+2) [Q3]
40% more funds holding
Funds holding: 154 [Q2] → 215 (+61) [Q3]
7% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 59
6.0% less ownership
Funds ownership: 103.97% [Q2] → 97.96% (-6.0%) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$24
12%
upside
Avg. target
$28
32%
upside
High target
$35
63%
upside
3 analyst ratings
1 positive
33%
2 neutral
67%
0 negative
0%
Wells Fargo Brandon Couillard 44% 1-year accuracy 8 / 18 met price target | 12%upside $24 | Equal-Weight Upgraded | 15 Jan 2025 |
HC Wainwright & Co. Yi Chen 40% 1-year accuracy 62 / 156 met price target | 21%upside $26 | Neutral Reiterated | 14 Jan 2025 |
BTIG Sung Ji Nam 60% 1-year accuracy 12 / 20 met price target | 63%upside $35 | Buy Maintained | 5 Nov 2024 |
Financial journalist opinion
Based on 3 articles about CDNA published over the past 30 days
Positive
Zacks Investment Research
6 days ago
Strength Seen in CareDx (CDNA): Can Its 6.1% Jump Turn into More Strength?
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Neutral
Business Wire
1 week ago
CareDx Announces Preliminary Fourth Quarter and Full Year 2024 Results
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – today reported preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2024. Preliminary Fourth Quarter 2024 Financial Results Revenue is expected to be between $85 million and $86 million, an increase of approximately 30% year-over-year. Testing services revenue is expected to be between $62.5 million and $63.5 million, an increase of approximately 35% year-over-y.
Positive
Seeking Alpha
3 weeks ago
CareDx: Top Of My Shopping List For 2025
CareDx is a promising candidate for the Bioreactor growth portfolio due to its leadership in transplant diagnostics and significant growth potential despite previous concerns. The company has shown strong revenue growth, with Q3 2023 revenue up 23% YoY, and maintains a robust balance sheet with $241M in cash and no debt. Key risks include potential slow adoption by transplant centers, competition from major players like Natera, and macroeconomic factors affecting the transplant market.
Neutral
Business Wire
1 month ago
CareDx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that the company will participate in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. CareDx's management is scheduled to present on Tuesday, January 14, 2025, at.
Neutral
Business Wire
1 month ago
CareDx Partners with TC BioPharm to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx will partner with TC BioPharm to perform pharmacokinetic analysis using its AlloCell™ solution in the ACHIEVE clinical trial. AlloCell has been used in ten prior cell therapy clin.
Neutral
PRNewsWire
1 month ago
TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy
EDINBURGH, Scotland , Dec. 11, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced a partnership with CareDx, Inc. (NASDAQ: CDNA) The Transplant Company™ who will perform pharmacokinetic analysis using its AlloCell™ solution in the ACHIEVE clinical trial. The ACHIEVE clinical trial is an adaptive, open-label, phase II study designed to evaluate the efficacy and effectiveness of TCB008, an allogeneic gamma delta T cell therapy for patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS).
Positive
Zacks Investment Research
1 month ago
Has CareDx (CDNA) Outpaced Other Medical Stocks This Year?
Here is how CareDx (CDNA) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Predict a 49.89% Upside in CareDx (CDNA): Here's What You Should Know
The consensus price target hints at a 49.9% upside potential for CareDx (CDNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Negative
Zacks Investment Research
2 months ago
After Plunging -11.97% in 4 Weeks, Here's Why the Trend Might Reverse for CareDx (CDNA)
The heavy selling pressure might have exhausted for CareDx (CDNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Negative
Zacks Investment Research
2 months ago
Are Medical Stocks Lagging CareDx (CDNA) This Year?
Here is how CareDx (CDNA) and Doximity (DOCS) have performed compared to their sector so far this year.
Charts implemented using Lightweight Charts™